3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
49
Carboplatin
44
Magnetic Resonance Spectroscopy
40
Specimen Handling
39
Pemetrexed
34
Cisplatin
25
Blood Specimen Collection
25
durvalumab
17
Paclitaxel
16
osimertinib
15
Radiotherapy
15
Radiosurgery
15
Bevacizumab
15
Gemcitabine
14
atezolizumab
13
Nivolumab
13
Biopsy
13
Drug Therapy
12
Standard of Care
10
Practice Guidelines as Topic
10
Immunoglobulin G
10
Docetaxel
10
130-nm albumin-bound paclitaxel
10
X-Rays
9
Taxes
9
Educational Status
9
Disulfides
9
tislelizumab
8
Etoposide
8
Cetuximab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lung Neoplasms
×
Histamine H2 Antagonists
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled